Newtyn Management, LLC Adverum Biotechnologies, Inc. Transaction History

Newtyn Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.75 - $1.26 $151,428 - $254,399	-201,904 Reduced 19.7%	823,096 $617,000
Q3 2023 Nov 14, 2023	BUY	$1.5 - $2.33 $37,500 - $58,250	25,000 Added 2.5%	1,025,000 $1.54 Million
Q2 2023 Aug 14, 2023	SELL	$0.68 - $1.59 $359,312 - $840,156	-528,400 Reduced 34.57%	1,000,000 $1.59 Million
Q1 2023 May 15, 2023	SELL	$0.62 - $0.85 $66,092 - $90,610	-106,600 Reduced 6.52%	1,528,400 $1.1 Million
Q4 2022 Feb 14, 2023	BUY	$0.54 - $10.3 $396,900 - $7.57 Million	735,000 Added 81.67%	1,635,000 $948,000
Q3 2022 Nov 14, 2022	SELL	$0.96 - $9.68 $129,600 - $1.31 Million	-135,000 Reduced 13.04%	900,000 $855,000
Q2 2022 Aug 15, 2022	BUY	$0.81 - $1.34 $838,350 - $1.39 Million	1,035,000 New	1,035,000 $1.24 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Newtyn Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Newtyn Management, LLC with notifications on news.